Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cytarabine/methotrexate

Cytarabine/methotrexate Reactions 1704, p128 - 2 Jun 2018 Various toxicities: case report A 56-year-old man developed leukocytoclastic vasculitis, acute kidney injury, febrile neutropenia and thrombocytopenia during treatment with methotrexate and cytarabine [Ara-C; not all routes stated] for primary central nervous system lymphoma (PCNSL). The man, who was diagnosed with PCNSL, started receiving treatment with high dose methotrexate 3 g/m infused over a period of 24 hours on day 1 with folinic acid rescue therapy and high dose cytarabine 2 g/m twice daily on days 2 and 3, planned for 6 8 cycles of chemotherapy administered every three weeks. Initially, the treatment with methotrexate and cytarabine was well tolerated. After approximately 14 days, he developed grade 2 febrile neutropenia with absolute neutrophil count nadir of 300 cells/mm , grade 1 acute kidney injury, grade 2 thrombocytopenia with a platelet count nadir of 3 3 32000 × 10 /mm and a grade 3 rash, which involved violaceous plaque and mainly affected the lower limbs and genitals. Consequently, the man was hospitalised. He was treated with imipenem/cilastatin and filgrastim. After 48 hours, all blood cultures, infection markers and all other biologic tests for autoimmune vasculitis were negative. His thrombocytopenia resolved. A skin biopsy http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Cytarabine/methotrexate

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018

Cytarabine/methotrexate

Abstract

Reactions 1704, p128 - 2 Jun 2018 Various toxicities: case report A 56-year-old man developed leukocytoclastic vasculitis, acute kidney injury, febrile neutropenia and thrombocytopenia during treatment with methotrexate and cytarabine [Ara-C; not all routes stated] for primary central nervous system lymphoma (PCNSL). The man, who was diagnosed with PCNSL, started receiving treatment with high dose methotrexate 3 g/m infused over a period of 24 hours on day 1 with folinic acid rescue therapy...
Loading next page...
 
/lp/springer_journal/cytarabine-methotrexate-EaGojEni7C

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46771-3
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p128 - 2 Jun 2018 Various toxicities: case report A 56-year-old man developed leukocytoclastic vasculitis, acute kidney injury, febrile neutropenia and thrombocytopenia during treatment with methotrexate and cytarabine [Ara-C; not all routes stated] for primary central nervous system lymphoma (PCNSL). The man, who was diagnosed with PCNSL, started receiving treatment with high dose methotrexate 3 g/m infused over a period of 24 hours on day 1 with folinic acid rescue therapy and high dose cytarabine 2 g/m twice daily on days 2 and 3, planned for 6 8 cycles of chemotherapy administered every three weeks. Initially, the treatment with methotrexate and cytarabine was well tolerated. After approximately 14 days, he developed grade 2 febrile neutropenia with absolute neutrophil count nadir of 300 cells/mm , grade 1 acute kidney injury, grade 2 thrombocytopenia with a platelet count nadir of 3 3 32000 × 10 /mm and a grade 3 rash, which involved violaceous plaque and mainly affected the lower limbs and genitals. Consequently, the man was hospitalised. He was treated with imipenem/cilastatin and filgrastim. After 48 hours, all blood cultures, infection markers and all other biologic tests for autoimmune vasculitis were negative. His thrombocytopenia resolved. A skin biopsy

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.